MYNZ · Mainz Biomed N.V. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $181.7K | $139.2K | $100.6K | - |
| Cost of Revenue | - | - | - | - | - | - | $94.5K | $100.1K | $54.1K | - |
| Gross Profit | - | - | - | - | - | - | $18.6K | $80.8K | $46.4K | - |
| R&D | $88.7K | - | - | - | - | - | $1.85M | $3.48M | $563.6K | - |
| SG&A | $2.12M | - | - | - | - | - | $2.75M | $4.93M | $1.59M | - |
| Total Operating Expenses | $2.46M | - | - | - | - | - | - | - | - | - |
| D&A | $160.8K | - | - | - | - | - | - | - | - | - |
| Operating Income | ($2.75M) | - | - | - | - | - | ($5.48M) | ($6.95M) | ($5.63M) | - |
| Interest Expense | $30.5K | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.00M) | - | - | - | - | - | ($5.60M) | ($6.94M) | ($6.56M) | - |
| EPS - Basic | ($0.43) | - | - | - | - | - | ($0.39) | ($0.48) | ($0.45) | - |
| EPS - Diluted | ($1.46) | - | - | - | - | - | ($0.39) | ($0.56) | ($0.42) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.70M | $889.1K | $1.91M | $6.24M | $977.8K | $7.07M | $9.32M | $10.91M | $29.97M | $17.14M |
| Accounts Receivable | - | - | $40.1K | $33.6K | $139.4K | $93.6K | $108.6K | $370.9K | $449.4K | $259.1K |
| Inventory | - | $216.9K | $503.1K | $372.9K | $520.5K | $613.6K | $493.6K | $387.2K | $266.1K | $175.5K |
| Accounts Payable | $150.2K | $411.1K | $1.14M | $1.33M | $2.90M | $3.45M | - | - | - | $2.72M |
| Current Assets | $6.60M | $1.84M | $3.09M | $8.02M | $2.39M | $8.98M | $10.98M | $12.13M | $12.32M | $18.38M |
| Total Assets | $7.72M | $5.33M | $9.80M | $13.50M | $8.45M | $15.41M | $17.91M | $19.31M | $19.54M | $20.24M |
| Current Liabilities | $3.13M | $3.69M | $5.99M | $6.18M | $10.01M | $9.24M | $11.26M | $10.71M | $6.70M | $4.24M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.13M | $4.69M | $7.28M | $7.50M | $12.59M | $12.16M | $14.46M | $14.13M | $9.86M | $6.14M |
| Stockholders' Equity | $2.38M | $641.6K | $2.52M | $6.00M | ($4.14M) | $3.35M | $3.45M | $5.18M | $9.68M | $14.10M |
| Retained Earnings | ($109.98M) | ($104.90M) | ($99.32M) | ($88.69M) | ($80.35M) | ($69.33M) | ($64.14M) | ($57.84M) | ($49.59M) | ($43.03M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.94M) | - | - | - | - | - | - | - | ($2.76M) | - |
| Investing Cash Flow | ($198.0K) | - | - | - | - | - | - | - | ($1.40M) | - |
| Financing Cash Flow | $7.27M | - | - | - | - | - | - | - | $24.11M | - |
| CapEx | $1.2K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($3.94M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | 10.2% | 58.0% | 46.2% | - |
| Operating margin | - | - | - | - | - | - | -3014.0% | -4989.9% | -5599.9% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | -3080.5% | -4983.3% | -6524.1% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.79 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | 1021.0% | 2498.3% | 560.4% | - |
| SG&A / Revenue | - | - | - | - | - | - | 1514.2% | 3542.4% | 1581.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -64.8% | - | - | - | - | - | -31.3% | -35.9% | -33.6% | - |
| Return on equity | -210.3% | - | - | - | - | - | -162.2% | -134.0% | -67.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.11 | 0.50 | 0.52 | 1.30 | 0.24 | 0.97 | 0.97 | 1.13 | 1.84 | 4.33 |
| Quick ratio | 2.11 | 0.44 | 0.43 | 1.24 | 0.19 | 0.91 | 0.93 | 1.10 | 1.80 | 4.29 |
| Cash ratio | 1.50 | 0.24 | 0.32 | 1.01 | 0.10 | 0.77 | 0.83 | 1.02 | 4.47 | 4.04 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -89.9x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.24 | 8.30 | 3.89 | 2.25 | -2.04 | 4.60 | 5.19 | 3.73 | 2.02 | 1.44 |
| Liabilities / Assets | 0.41 | 0.88 | 0.74 | 0.56 | 1.49 | 0.79 | 0.81 | 0.73 | 0.50 | 0.30 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.01 | 0.01 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | 0.19 | 0.26 | 0.20 | - |
| Days sales outstanding | - | - | - | - | - | - | 218d | 972d | 1631d | - |
| Days inventory outstanding | - | - | - | - | - | - | 1907d | 1411d | 1794d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -89.3% | - | 78.9% | - | -76.2% | - | - | - | 121.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing MAINZ BIOMED N.V. against the 5 most active filers in the same SIC group.